BriaCell (BCTX) Therapeutics announces the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study: Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026. BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician’s choice in advanced metastatic breast cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell’s Phase 3 Study in Metastatic Breast Cancer Receives Positive DSMB Recommendation
- BriaCell reports iDSMB has completed third scheduled safety data review
- BriaCell Reports Increased Losses in Latest Financials
- BriaCell Therapeutics Schedules Virtual Investor Presentations for June 2025
- Promising Phase 2 Results and Safety Profile Support Buy Rating for BriaCell Therapeutics